



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/001,755	10/24/2001	Peter William Taylor	4-20251/C/MA 2102/PCT/CON

O I P E
 FEB 12 2002
 001095
 THOMAS HOXIE
 NOVARTIS CORPORATION
 PATENT AND TRADEMARK DEPT
 564 MORRIS AVENUE
 SUMMIT, NJ 079011027

CONFIRMATION NO. 5831

FORMALITIES LETTER



OC000000007229615

Date Mailed: 12/26/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:


- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586727US
Express Mail Label Number

February 12, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1642

TAYLOR ET AL.

APPLICATION NO: 10/001,755

FILED: OCTOBER 24, 2001

FOR: LIPOSOMAL INTERFERON HYBRID COMPOSITION

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

The Notice to File Corrected Application Papers - Filing Date Granted dated December 26, 2001 (a copy of which is enclosed) has a shortened statutory time set to expire on February 26, 2002.

In response, applicants now submit an abstract of the technical disclosure as required under 37 CFR §1.72(b).

Applicants believe that no fee is required. If a fee is required, the Commissioner is hereby authorized to charge such fees to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

John Thallemer
John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950
Date: February 12, 2002